期刊
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 81, 期 1, 页码 1-12出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2022.10.013
关键词
hypercholesterolemia; hyperlipidemia; LDL-C; lipids; statin; supplements
This study compared the efficacy of a low-dose statin with placebo and 6 common supplements in impacting lipid and inflammatory biomarkers. The results showed that rosuvastatin significantly lowered LDL-C compared to placebo and each supplement. None of the dietary supplements demonstrated a significant decrease in LDL-C compared to placebo.
BACKGROUND Supplements are commonly used by individuals with indications for lipid-lowering therapy, but evidence of their effectiveness to lower low-density lipoprotein cholesterol (LDL-C) is lacking, particularly when compared with statins. OBJECTIVES The trial objective was to compare the efficacy of a low-dose statin with placebo and 6 common supplements in impacting lipid and inflammatory biomarkers. METHODS This was a single-center, prospective, randomized, single-blind clinical trial among adults with no history of atherosclerotic cardiovascular disease (ASCVD), an LDL-C of 70 to 189 mg/dL, and an increased 10-year risk of ASCVD. Participants were randomized to rosuvastatin 5 mg daily, placebo, fish oil, cinnamon, garlic, turmeric, plant sterols, or red yeast rice. The primary endpoint was the percent change in LDL-C from baseline for rosuvastatin 5 mg daily compared with placebo and each supplement after 28 days. The primary endpoint was evaluated in a hierarchical fashion with rosuvastatin first compared with placebo, then each supplement in a prespecified order using analysis of covariance.RESULTS A total of 190 participants completed the study. The percent LDL-C reduction with rosuvastatin was greater than all supplements and placebo (P < 0.001). The difference in LDL-C reduction with rosuvastatin compared with placebo was-35.2% (95% CI:-41.3% to -29.1%; P < 0.001). None of the dietary supplements demonstrated a significant decrease in LDL-C compared with placebo. Adverse event rates were similar across study groups.CONCLUSIONS Among individuals with increased 10-year risk for ASCVD, rosuvastatin 5 mg daily lowered LDL-C significantly more than placebo, fish oil, cinnamon, garlic, turmeric, plant sterols, and red yeast rice. (Supplements, Placebo, or Rosuvastatin Study [SPORT]; NCT04846231) (J Am Coll Cardiol 2023;81:1-12)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据